Abstracts Archive - Page 787 of 2607 - ACR Meeting Abstracts

Abstract Number: 1228 • ACR Convergence 2021
Predicting RA Remission with Subcutaneous Abatacept Treatment in the Real-world Setting
Rieke Alten¹, Christiane Rauch², Bettina Bannert³, Sara Marsal⁴, Maya Buch⁵, Roberto Caporali⁶, Melanie Chartier⁷, Sean Connolly⁸, Hedley Griffiths⁹, Xavier Mariette¹⁰, Michael Nurmohamed¹¹, Yusuf Patel¹², Peter Peichl¹³, Raimon Sanmarti¹⁴, Yedid Elbez¹⁵ and Karissa Lozenski⁸, ¹Schlosspark-Klinik University, Berlin, Germany, ²Bristol Myers Squibb, Munich, Germany, ³Universitätsspital Basel, Basel, Switzerland, ⁴Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁵University of Leeds, Leeds, United Kingdom, ⁶Policlinico S. Matteo University, Pavia, Italy, ⁷Bristol Myers Squibb, Rueil-Malmaison, France, ⁸Bristol Myers Squibb, Princeton, NJ, ⁹Barwon Rheumatology Service, Geelong, Australia, ¹⁰Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ¹¹ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, ¹²Hull Royal Infirmary, Hull, United Kingdom, ¹³Evangelical Hospital, Vienna, Austria, ¹⁴Hospital Clínic de Barcelona, Barcelona, Spain, ¹⁵Deepscover, Puteaux, France
Background/Purpose: A treat-to-target approach for RA management is recommended, with the aim of achieving remission.1,2 The Abatacept SubCutaneOus in Routine clinical practicE (ASCORE; NCT02090556) study…
Abstract Number: 1229 • ACR Convergence 2021
Does BMI Influence the Efficacy of Subcutaneous or Intravenous Abatacept in Patients with RA in Routine Clinical Practice? A Post Hoc Analysis of Two Real-world Observational Studies
Rieke Alten¹, Xavier Mariette², Melanie Chartier³, Christiane Rauch⁴, Yedid Elbez⁵, Karissa Lozenski⁶ and Vadim Khaychuk⁶, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³Bristol Myers Squibb, Rueil-Malmaison, France, ⁴Bristol Myers Squibb, Munich, Germany, ⁵Deepscover, Puteaux, France, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: BMI has been shown to affect treatment response and may influence the development of optimal individualized treatment plans in patients with RA.1 The extent…
Abstract Number: 1230 • ACR Convergence 2021
Impact of Serologic Status on Clinical Responses to Upadacitinib or Abatacept in Patients with Rheumatoid Arthritis and Prior Inadequate Response to Biologic DMARDs: Sub-Group Analysis from the Phase 3 SELECT-CHOICE Study
Andrea Rubbert-Roth¹, Jeffrey Sparks², Arnaud Constantin³, Ricardo Xavier⁴, Yanna Song⁵, Jessica Suboticki⁵ and Roy Fleischmann⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³Toulouse University Hospital, Toulouse Cedex 9, France, ⁴Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁵AbbVie Inc., North Chicago, IL, ⁶University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients with RA who had a prior inadequate response or intolerance to biologic DMARDs, the oral Janus kinase inhibitor, upadacitinib (UPA), demonstrated superiority…
Abstract Number: 1231 • ACR Convergence 2021
Consistent Impact of Autoantibody Enrichment Across All ACR Core Measures in Early Rheumatoid Arthritis Treated with Abatacept: Data from a Large Pooled Analysis of 4 Randomized Controlled Trials
Philip Conaghan¹, Sang Hee Park², Mirko Fillbrunn³, Karissa Lozenski², Vadim Khaychuk², Kaleb Michaud⁴, Elyse Swallow³, Henry Lane³, Ha Nguyen³ and Janet Pope⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Bristol Myers Squibb, Princeton, NJ, ³Analysis Group, Inc., Boston, MA, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Western Ontario, London, ON, Canada
Background/Purpose: Biomarkers play an important role in RA and can help guide treatment decisions. Previous studies have suggested differential treatment efficacy of abatacept (ABA) in…
Abstract Number: 1232 • ACR Convergence 2021
Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients
Matthew Turk¹, Candice Low², Carl Orr³, Richard Conway⁴, Kieran Murray⁵, Ursula Fearon⁶ and Douglas Veale⁷, ¹St. Vincents University Hospital, Dublin, Ireland, ²St. Vincent's University Hospital, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland, ⁴St. James's University Hospital, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Dublin, Ireland, ⁶Trinity College Dublin, Dublin, Ireland, ⁷University College Dublin, Dublin, Ireland
Background/Purpose: Activated B lymphocytes and plasma cells are implicated in the pathogenesis of rheumatoid arthritis (RA). The anti-CD20 monoclonal antibody therapy (Rituximab) is an effective…
Abstract Number: 1233 • ACR Convergence 2021
Physician and Patient Reported Effectiveness Outcomes Are Similar in Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Registry in Canada
Mohammad Movahedi¹, Angela Cesta², Xiuying Li², Edward Keystone³ and Claire Bombardier⁴, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ³Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁴University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment as an alternative option to biologic disease modifying antirheumatic drugs…
Abstract Number: 1234 • ACR Convergence 2021
Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy
Martin Bergman¹, Maya Buch², Yoshiya Tanaka³, Gustavo Citera⁴, Sami Bahlas⁵, Ernest Wong⁶, Yanna Song⁷, Namita Tundia⁷, Jessica Suboticki⁷ and Vibeke Strand⁸, ¹Martin Jan Bergman, MD, Ridley Park, PA, ²University of Leeds, Leeds, United Kingdom, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁵Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, ⁶Rheumatology, Queen Alexandra Hospital, Portsmouth, United Kingdom, ⁷AbbVie Inc., North Chicago, IL, ⁸Stanford University School of Medicine, Portola Valley, CA
Background/Purpose: Routine Assessment of Patient Index Data 3 (RAPID3) is a pooled index of 3 patient-reported measures: patient global assessment, pain, and physical function. RAPID3…
Abstract Number: 1235 • ACR Convergence 2021
Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials
Bruno Fautrel¹, Bochao Jia², Jianmin Wu³, Ju Ji², Julie Birt², Ewa Haladyj² and Tsutomu Takeuchi⁴, ¹Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianaplolis, IN, ⁴Div. Rheumatology, Keio University, Tokyo, Japan
Background/Purpose: Fatigue is very common in rheumatoid arthritis (RA) and impairs patient quality of life. Baricitinib (BARI) improved fatigue, pain and other patient-reported outcomes (PROs)…
Abstract Number: 1236 • ACR Convergence 2021
Pain in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints with Baricitinib Clinical Trials
Anthony Sebba¹, Duzhe Wang², Bochao Jia², Jason Troutt², Julie Birt², Amanda Quebe³ and Peter C Taylor⁴, ¹Division of Rheumatology, University of South Florida, Tampa, FL, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indanapolis, IN, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib (BARI) is a Janus kinase (JAK)1/JAK2 inhibitor which provides improvements to clinical signs, symptoms, and patient-reported outcomes (PROs) in patients with rheumatoid arthritis…
Abstract Number: 1237 • ACR Convergence 2021
Predictors of Response: Baseline Characteristics and Early Treatment Responses Associated with Achievement of Remission and Low Disease Activity Among Upadacitinib-Treated Patients with Rheumatoid Arthritis
Arthur Kavanaugh¹, Zoltan Szekanecz², Edward Keystone³, Andrea Rubbert-Roth⁴, Stephen Hall⁵, Ricardo Xavier⁶, Joaquim Pereira⁷, In-Ho Song⁸, Naomi Martin⁹, Yanna Song⁸, Samuel Anyanwu⁸ and Peter Nash¹⁰, ¹Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA, ²Division of Rheumatology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, ³Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁴Kantonspital St Gallen, St.Gallen, Switzerland, ⁵Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ⁶Departamento de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁷Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte and Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon Academic Medical Centre, Lisbon, Portugal, ⁸AbbVie Inc., North Chicago, IL, ⁹AbbVie Inc., Saint-Laurent, QC, Canada, ¹⁰Griffith University, Brisbane, Australia
Background/Purpose: Early prediction of response to treatment with upadacitinib (UPA) 15 mg once daily (QD) could help optimize therapy in patients (pts) with RA.1-4 The…
Abstract Number: 1238 • ACR Convergence 2021
Low Patient Global Assessment of Disease Activity and Negative Rheumatoid Factor Are Strongly Associated with Likelihood of Maintaining Remission Following Tapering of Therapy in Patients with Rheumatoid Arthritis
Jeffrey Curtis¹, Paul Emery², Boulos Haraoui³, Greg Kricorian⁴, Priscilla Yen⁴, David Collier⁵ and Vivian Bykerk⁶, ¹Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ³Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Amgen Inc., Simi Valley, CA, ⁶Hospital for Special Surgery, New York, NY
Background/Purpose: According to ACR and EULAR recommendations, patients with rheumatoid arthritis (RA) who persist in remission (REM) should consider tapering RA therapy. Identification of clinical…
Abstract Number: 1239 • ACR Convergence 2021
Differences in Patient-Reported Outcomes Between Those Who Stay in Remission and Those Who Have Disease-Worsening Following Therapy Withdrawal in Patients with Rheumatoid Arthritis
Vivian Bykerk¹, Jeffrey Curtis², Paul Emery³, Boulos Haraoui⁴, Elaine Karis⁵, Greg Kricorian⁵, David Collier⁶, Priscilla Yen⁵ and Bradley Stolshek⁵, ¹Hospital for Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds NIHR Biomedical Research Centre, Leeds, United Kingdom, ⁴Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Amgen Inc., Simi Valley, CA
Background/Purpose: Patients with RA in remission (REM) may experience disease-worsening (DW) following therapy change or withdrawal. The change in patient-reported outcomes (PROs) after therapy withdrawal…
Abstract Number: 1240 • ACR Convergence 2021
Biomarker Driven Dissection of Inflammation Modulatory Effects of Upadacitinib versus Abatacept in Patients with Active Rheumatoid Arthritis Refractory to Biologic DMARDs
Fang Cai¹, Thierry Sornasse², Feng Hong³, Heidi Camp⁴, Koji Kato⁵ and Iain McInnes⁶, ¹AbbVie, Redwood City, CA, ²AbbVie Inc, Redwood City, CA, ³AbbVie, Worcester, MA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, Shinagawa- Ku, Japan, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: In patients with active rheumatoid arthritis (RA) refractory to biologic DMARDs (bDMARD-IR), a phase 3, double-blind and active-controlled study (SELECT-CHOICE) demonstrated that upadacitinib (UPA)…
Abstract Number: 1241 • ACR Convergence 2021
Comparison of the Effects of Upadacitinib Monotherapy with MTX on Protein Biomarkers in MTX-Naïve and MTX-Inadequate Responders in Patients with Active Rheumatoid Arthritis: Results from the SELECT-EARLY and SELECT‑MONOTHERAPY Phase 3 Studies
Thierry Sornasse¹, Heidi Camp², Fang Cai³, Justin Klaff² and Iain McInnes⁴, ¹AbbVie Inc, Redwood City, CA, ²AbbVie Inc., North Chicago, IL, ³AbbVie, Redwood City, CA, ⁴University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: In MTX-naïve patients (SELECT-EARLY/M13-545 Phase 3 study) UPA 15 mg QD monotherapy (UPA Mono) demonstrated significant and clinically meaningful improvements in RA signs and…
Abstract Number: 1242 • ACR Convergence 2021
Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis
Kristina Lend¹, Ronald F van Vollenhoven², Jon Lampa³, Merete Hetland⁴, Espen Haavardsholm⁵, Dan Nordström⁶, Michael Nurmohamed⁷, Bjorn Gudbjornsson⁸, Anna Rudin⁹, Mikkel Ostergaard¹⁰, Till Uhlig¹¹, Gerdur Grondal⁸, Kim Hørslev-Petersen¹², Marte S Heiberg⁵, Tuulikki Sokka-Isler¹³, Jos Twisk¹⁴ and Irene van der Horst-Bruinsma¹⁵, ¹Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, ²Amsterdam University Medical Centers, Department of Rheumatology and Clinical Immunology, Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, ³Karolinska University Hospital, Department of Medicine, Rheumatology Unit, The Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ⁴DANBIO and COPECARE, Centre for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Division of Internal Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland, ⁷Amsterdam University Medical Centers, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ⁸Landspitali University Hospital, University of Iceland, Reykjavik, Iceland, ⁹Rheumatology Clinic, Sahlgrenska University Hospital, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ¹⁰Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ¹¹Diakonhjemmet Hospital, University of Oslo, Oslo, Norway, ¹²Danish Hospital for Rheumatic Diseases, University of Southern Denmark, Reykjavik, Iceland, Haderslev, Denmark, ¹³University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland, ¹⁴Department of Epidemiology and Biostatistics, Amsterdam University Medical Centres, Amsterdam, Netherlands, ¹⁵Department of Rheumatology, VU University Medical Centre, Amsterdam, Netherlands
Background/Purpose: To investigate sex differences in clinical response to three different biological treatments in combination with methotrexate (MTX) versus MTX plus corticosteroids (active conventional treatment;…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].